Biomedical Engineering Reference
In-Depth Information
References
1. Burger, P.C., Dubois, P.J., Schold, S.C. Jr., Smith, K.R. Jr., Odom, G.L., et al.,
1983, “Computerized tomographic and pathological studies of the untreated,
quiescent, and recurrent glioblastoma multiforme,” J. Neurosurg., 58, pp. 159-
169.
2. Yung, W.K., Albright, R., Olson, J., Fredericks, R., Fink, K., et al., 2000, “A
phase II study of temozolamide vs. procarbazine in patients with glioblastoma
multiforme at first relapse,” Br. J. Cancer, 83, pp. 588-593.
3. Ruben, J.D., Dally, M., Bailey, M., Smith, R., Mclean, C.A., Fedele, P., 2006,
“Cerebral radiation necrosis: incidence, outcomes, and risk factors with
emphasis on radiation parameters and chemotherapy,” Int. J. Radiat. Oncol.
Biol. Phys., 65, pp. 499-508.
4. Caruso, G., Caffo, M., Alafaci, C., Raudino, G., Cafarella, D., et al., 2011,
“Could nanoparticles systems have a role in the treatment of cerebral gliomas?”
Nanomedicine, 7, pp. 744-752.
5. Caruso, G., Raudino, G., Caffo, M., Alafaci, C., Granata, F., 2010,
“Nanotechnology platforms in diagnosis and treatments of primary brain
tumors,” Recent Pat. Nanotechn., 4, pp. 119-122.
6. Chintala, S.K., Gokaslan, Z.L., Go, Y., Sawaya, R., Nicolson, G.L., Rao, J.S.,
1996, “Role of extracellular matrix proteins in regulation of human glioma cell
invasion
in vitro
,” Clin. Exp. Metastasis, 14, pp. 358-366.
7. Hanahan, D. and Folkman, J., 1996, “Patterns and emerging mechanisms of
the angiogenic switch during tumorigenesis,” Cell, 86, pp. 353-364.
8. Uhm, J.H., Dooley, N.P., Villemure, J.-G., Yong, V.W., 1997, “Mechanisms of
glioma invasion: role of matrix metalloproteinases,” Can. J. Neurol. Sci., 24,
pp. 3-15.
9. Gladson, C.L., 1996 “Expression of integrin alpha v beta 3 in small blood
vessels of glioblastoma tumors,” J. Neuropathol. Exp. Neurol., 55, pp. 1143-
1149.
10. Caffo, M., Germanò, A., Caruso, G., Meli, F., Galatioto, S., et al., 2004
“An immunohistochemical study of extracellular matrix proteins laminin,
fibronectin and type IV collagen in paediatric glioblastoma multiforme,” Acta
Neurochir. (Wien), 146, pp. 1113-1118.
11. Miner, J.H., 2008, “Laminins and their roles in mammals,” Microsc. Res. Tech.,
71, pp. 349-356.
12. Pardridge, W.M., 2003,“Blood-brain barrier drug targeting: the future of brain
drug development,” Mol. Interv., 3, pp. 90-105.
13. Egleton, R.D., and Davis, T.P., 1997, “Bioavailability and transport of peptides
and peptide drugs into the brain,” Peptides, 18, pp. 1431-1439.
14. Engelhardt, B., and Sorokin, L., 2009, “The blood-brain and the blood-
cerebrospinal fluid barriers: function and dysfunction,” Semin. Immunopathol.,
31, pp. 497-511.
15. Cardoso, F.L., Brites, D., Brito, M.A., 2010, “Looking at the blood-brain
barrier: molecular anatomy and possible investigation approaches,” Brain Res.
Rev., 64, pp. 328-363.
